Search results for "I line treatment"

showing 1 items of 1 documents

Network meta-analysis of randomized trials in multiple myeloma: Efficacy and safety in frontline therapy for patients not eligible for transplant

2022

The treatment scenario for newly-diagnosed transplant-ineligible multiple myeloma patients (NEMM) is quickly evolving. Currently, combinations of proteasome inhibitors (PI) and/or immunomodulatory drugs (IMiD) +/- the monoclonal antibody Daratumumab are used for first-line treatment, even if head-to-head comparisons are lacking. To compare efficacy and safety of these regimens, we performed a network meta-analysis (NMA) of 27 phase 2/3 randomized trials including a total of 12935 patients and 23 different schedules. Four efficacy/outcome and one safety indicators were extracted and integrated to obtain (for each treatment) the surface under the cumulative ranking-curve (SUCRA), a metric use…

multiple myelomaCancer ResearchOncologyprincipal component analysisnon-transplant eligibleI line treatment multiple myeloma network meta-analysis non-transplant eligible principal component analysisHematologyGeneral MedicineSettore MED/15 - Malattie del SangueI line treatmentnetwork meta-analysisI line treatment; multiple myeloma; network meta-analysis; non-transplant eligible; principal component analysis;
researchProduct